eligibility_summary
Eligibility: Kidney transplant candidates with genetic/immunologic CKD (e.g., SIOD, FSGS, cystinosis, SLE, MPGN, ANCA vasculitis) or prior graft rejection, CKD stage ≥3, steroids <0.5 mg/kg/day, donor and recipient share ≥1 high‑resolution allele at HLA‑A, ‑B, ‑Cw, ‑DQB1, ‑DRB1, performance score >50, consent, contraception. Exclude: pregnancy/lactation, >Grade II aGvHD or severe cGvHD, major liver/cardiac disease, unmanageable dialysis, active infection (unless controlled HIV/HBV/HCV), uncontrolled illness, no consent, or investigator‑judged high risk.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05508009 tests sequential αβ‑depleted allogeneic HSCT followed by living‑donor kidney transplant from the same HLA‑partially matched donor to induce tolerance and avoid maintenance immunosuppression. Interventions/mechanisms: • Cyclophosphamide (alkylating agent, lympho/myeloablation). • Fludarabine (purine analog, lymphodepletion). • Melphalan (alkylating agent, myeloablation). • Total body irradiation (lympho/myeloablation). • ATG (polyclonal anti‑T‑cell antibody, T‑cell depletion). • Rituximab (anti‑CD20 monoclonal antibody, B‑cell depletion). • CliniMACS TCRαβ/CD19 depletion (device‑based graft engineering removing TCRαβ+ T cells and CD19+ B cells to reduce GVHD and humoral alloimmunity). Targets/pathways: TCRαβ T cells, CD19/CD20 B cells, host lymphoid/myeloid compartments, alloreactive T‑ and B‑cell responses, establishment of donor hematopoietic chimerism to drive central/peripheral tolerance and prevent kidney graft rejection.